Haldol official prescribing information for healthcare professionals. Includes: indications, dosage, adverse reactions, pharmacology and more.
The patient should be carefully monitored, since recurrences of NMS have been reported. If a patient requires antipsychotic drug treatment after recovery from NMS, the potential reintroduction of drug therapy should be carefully considered.
Tissue culture experiments indicate that approximay one-third of human breast cancers are prolactin dependent in vitro, a factor of potential importance if the prescription of these drugs is contemplated in a patient with a previously detected breast cancer. An increase in mammary neoplasms has been found in rodents after chronic administration of antipsychotic drugs.
Find patient medical information for Haldol Oral on WebMD including its uses, side effects and safety, interactions, pictures, warnings and user ratings.
Are you currently treating this condition?
Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088 or at www.fda.gov/medwatch.
List Haldol Tablet side effects by likelihood and severity.
If you develop any of these symptoms, l your doctor right away. For males, it may result in decreased sexual ability, inability to produce sperm, or enlarged breasts. For females, this increase in prolactin may result in unwanted breast milk, missed/stopped periods, or difficulty becoming pregnant.
Haloperidol is a medication that works in the brain to treat schizophrenia. Read about Haloperidol and the treatment of schizophrenia.
All antipsychotics have been associated with the risk of sudden cardiac death due to an arrhythmia (irregular heart beat). To minimize this risk, antipsychotic medications should be used in the smallest effective dose when the benefits outweigh the risks. Your doctor may order an EKG to monitor for irregular heart beat.
All FDA black box warnings are at the end of this fact sheet.
Medscape - Indication-specific dosing for Haldol, Haldol Decanoate (haloperidol), frequency-based adverse effects, comprehensive interactions.
Severe neurotoxicity manifesting as rigidity or inability to walk or talk may occur in patients with thyrotoxicosis also receiving antipsychotics.
Use caution in patients at risk of pneumonia (eg, Alzheimer's patients); antipsychotic use reported to be associated with esophageal dysmotility and aspiration.
Duration: 2-4 weeks (decanoate).
Metabolized by hepatic P450 enzyme CYP3A4 Metabolites: Hydroxyhaloperidol Enzymes inhibited: CYP2D6.
Peak plasma time: 2-6 hr (PO); 10-20 minutes(IM); 6-7 days (decanoate) Protein bound: 90% Vd: 8-18 L/kg.
>12 years: 0.5-2 mg PO q8-12hr initially; if severe symptoms necessitate increased dosage, titrate upward to 3-5 mg PO q8-12hr; if patient remains inadequay controlled, daily doses up to 100 mg have been used (safety not determined).
>12 years: Moderate disease, 0.5-2 mg PO q8-12hr initially; severe disease, 3-5 mg PO q8-12hr; not to exceed 30 mg/day.
Motor instability, somnolence, and orthostatic hypotension reported, which may lead to falls and, consequently, fractures or other fall-related injuries; assess risk of falls when initiating treatment and recurrently for patients receiving repeated doses, particularly the elderly, with diseases, conditions, or medications that could exacerbate these effects.
FDA warning regarding off-label use for dementia in elderly.
Decreased sensation of thirst due to central inhibition may lead to dehydration, hemoconcentration and reduced pulmonary ventilation; a number of cases of bronchopneumonia, some fatal, reported; if signs and symptoms appear, especially in the elderly, institute remedial therapy promptly.
Caution in patients receiving anticoagulants; isolated instance of interference occurred with effects of one anticoagulant (phenindione).
By clicking send, you acknowledge that you have permission to the recipient with this information.
<3 years: Safety and efficacy not established.
Avoid use in narrow angle glaucoma, bone marrow suppression, and severe hypotension.
Leukopenia/neutropenia and agranulocytosis reported; possible risk factors include preexisting low white blood cell (WBC) count and history of drug-induced leukopenia/neutropenia.
The recipient will receive more details and instructions to access this offer.
Half-life: 18 hr; 3 weeks (decanoate).
IV (off-label): 0.25-0.5 mg IV q4hr; use only lactate (not decanoate) for IV administration; monitor with ECG for prolonged QT interval.
Conditions or drugs that prolong QT interval, congenital long QT syndrome.
3-12 years: 0.5 mg/day PO initially; dose increased PRN by 0.5 mg every 5-7 days until therapeutic effect achieved, then reduced to lowest effective maintenance level of 0.05-0.075 mg/kg/day PO divided q8-12hr.
>12 years: 0.5-3 mg PO, repeated in 1 hour PRN; alternatively, 2-5 mg IM, repeated in 1 hr PRN.
Adding plans allows you to compare formulary status to other drugs in the same class.
Risk of sudden death, torsades de pointes, and prolonged QT interval from off-label IV administration of higher than recommended dose: monitor ECG if administering IV.
Haloperidol lactate and haloperidol decanoate are both administered IM; haloperidol lactate has also been administered IV (off-label); haloperidol decanoate should not be administered IV.
When used to control mania in cyclic disorders, there may be rapid mood swing to depression.
Impairment of core body temperature regulation reported; use caution with activities that may increase body temperature including strenuous exercise, heat exposure, dehydration, and concomitant medications with anticholinergic effects.
<3 years: Safety and efficacy not established.
If administering IV or IM, watch for hypotension; use with caution in diagnosed CNS depression, subcortical brain damage, or cardiac disease; if history of seizures, benefits must outweigh risks; significant increase in body temperature may indicate intolerance to antipsychotics (discontinue if this occurs).
IM decanoate (depot): Lower initial doses and more gradual adjustments recommended; monthly dose 10-15 times daily PO dose.
If patient has history of clinically significant presence of either risk factor, monitor complete blood count (CBC) frequently during first few months of therapy; discontinue drug at first sign of clinically significant WBC decline <1000/μL in absence of other causative factors, and continue monitoring WBC count until recovery.
Excretion: Urine (30%), feces (15%).
<12 years: Safety and efficacy not established.
Use caution in patients receiving anticonvulsant medications, with a history of seizures, or with EEG abnormalities; haloperidol may lower convulsive threshold; if indicated, adequate anticonvulsant therapy should be concomitantly maintained.
6-12 years: Lactate (prompt-acting): 1-3 mg IM q4-8hr PRN; not to exceed 0.15 mg/kg/day.
Positive evidence of human fetal risk.
Pictures of Haldol (Haloperidol Injection), drug imprint information, side effects for the patient.
If you do not have a dose-measuring device, ask your pharmacist for one. Measure liquid medicine with the dosing syringe provided, or with a special dose-measuring spoon or medicine cup.
Taking too much haloperidol can cause a serious heart rhythm disorder or sudden death. Never take more than your prescribed dose.
round, orange, imprinted with MYLAN 327.
Your doctor may occasionally change your dose to make sure you get the best results. Follow all directions on your prescription label.